Cross-Protective Vaccine for Piglets Using Serotype 5 Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Haemophilus parasuis serotype 4 are ineffective as they do not provide cross-protection, requiring separate vaccines for serotypes 4 and 5, which increases safety and economic risks due to higher bacterial content and contamination chances.
Innovation Solution
A vaccine using inactivated Haemophilus parasuis serotype 5 bacteria administered to pregnant sows or gilts provides protection against serotype 4 through colostrum intake in piglets, utilizing inactivated cells or derivatives as antigens, potentially with a two-dose vaccination schedule before farrowing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If separate vaccines for serotypes 4 and 5 are used, then protection coverage is improved, but safety and economic risks worsen due to higher bacterial content and contamination chances
Solution Approach 1:
The patent applies universality by developing a single vaccine composition that provides protection against multiple serotypes (4 and 5) of Haemophilus parasuis. The vaccine includes inactivated bacteria of both serotypes in one formulation, allowing one vaccine to perform multiple protective functions simultaneously, thereby covering the protection gap without requiring separate vaccinations for each serotype.
Solution Approach 2:
The patent merges previously separate vaccine formulations into a single combined vaccine. By incorporating inactivated H. parasuis serotype 4 and serotype 5 bacteria together in one vaccine composition, the patent eliminates the need for separate vaccines while reducing the total bacterial content and contamination risk associated with multiple separate formulations.
2Adaptability or versatility
If both serotypes 4 and 5 are included in the vaccine, then cross-protection is improved, but manufacturing complexity and contamination risk worsen
Solution Approach 1:
The patent combines the manufacturing processes for serotype 4 and serotype 5 vaccines into a single integrated production system. By formulating both serotypes in one vaccine composition using a unified manufacturing approach, the patent reduces the complexity of producing and managing multiple separate vaccine lines while ensuring consistent quality and safety standards.
Solution Approach 2:
The vaccine composition is designed with universal applicability against multiple serotypes, allowing a single manufacturing process to produce a vaccine that provides cross-protection. This multi-functional vaccine formulation simplifies production protocols, quality control procedures, and distribution logistics compared to maintaining separate manufacturing systems for each serotype.
3Reliability
If two-dose vaccination schedule is used, then immunogenicity is improved, but time and cost worsen
Solution Approach 1:
The patent implements a periodic vaccination schedule with two doses administered at intervals (e.g., 2-4 weeks apart) to optimize immunogenicity. This periodic administration allows the immune system to develop progressive immunity, with the first dose initiating the immune response and the second dose boosting antibody production, achieving superior protection compared to single-dose regimens.
Solution Approach 2:
The vaccination protocol is designed to be administered preliminarily to sows or gilts before they are introduced to infected farms or before farrowing. This preliminary immunization ensures that protective antibodies are present in the dam's colostrum before piglets are exposed to pathogens, providing passive immunity to the newborns during their most vulnerable period.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces clinical signs and mortality in piglets challenged with Haemophilus parasuis serotype 4, demonstrating effective protection via passive immunity from colostrum-borne antibodies.
Implementation Method 1
provides protection against serotype 4 through colostrum intake in piglets, utilizing inactivated cells or derivatives as antigens
Implementation Method 2
demonstrating effective protection via passive immunity from colostrum-borne antibodies
Data Source
AI summary
The present invention pertains to the use of Haemophilus parasuis serotype 5 bacteria in the manufacture of a vaccine for administration to a pregnant sow or gilt, to protect a piglet through the intake of colostrum of the said sow or gilt after she has farrowed, against a disorder arising from Haemophilus parasuis serotype 4 bacteria. The invention also pertains to Haemophilus parasuis serotype 5 bacteria for use in the manufacture of such a vaccine.